CN1413584A - Antitumor oral medicine prepared by Chinese yew extract - Google Patents
Antitumor oral medicine prepared by Chinese yew extract Download PDFInfo
- Publication number
- CN1413584A CN1413584A CN 02132940 CN02132940A CN1413584A CN 1413584 A CN1413584 A CN 1413584A CN 02132940 CN02132940 CN 02132940 CN 02132940 A CN02132940 A CN 02132940A CN 1413584 A CN1413584 A CN 1413584A
- Authority
- CN
- China
- Prior art keywords
- ramulus
- folium taxi
- taxi cuspidatae
- cuspidatae extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oral-applied anticancer medicine for treating lung cancer, ovary cancer, breast cancer, etc is prepared from the Chinese yew's extract, which contains taxol (0.5-5 wt.%), taxalkyl diterpenoid compounds (5-25), tannin (20-30), polyose (20-30) and common flavone (20-30). Its advantages are high curative effect and low cost.
Description
Technical field: the present invention relates to a kind of medicine for the treatment of cancer.
Background technology: the Chinese at present number of dying from cancer every year is more than 1,400,000, and cancer has become the commonly encountered diseases of modern society's serious harm human health.The paclitaxel that extracts from Ramulus et folium taxi cuspidatae is the first-class cancer therapy drug in the whole world, the cancer therapy drug that present paclitaxel is made mainly is a paclitaxel injection, this injection is active ingredient owing to only relying on the paclitaxel monomer, therefore has following shortcoming: 1, can not embody the effect that the Chinese medicine compound compatibility uses; 2, toxic and side effects is big, and concrete manifestation is to cause bone marrow depression, neutrophilic granulocyte occurs and reduces and thrombocytopenia, and indivedual cases cardiac toxicity occurs and cardiac conduction is unusual, comprise myocardium conduction block once, cause phenomenons such as bradycardia and arrhythmia; 3, extract injection and make the consumed resource of Ramulus et folium taxi cuspidatae big, and the costing an arm and a leg of paclitaxel injection; 4, injection also has and is difficult for the shortcoming oral, that inconvenience is carried.
Summary of the invention: the present invention is that a series of problems that active ingredient caused are developed a kind of antitumor oral medicine made from Ramulus et folium taxi cuspidatae Extract for solving paclitaxel injection owing to only relying on the paclitaxel monomer.The present invention is that described Ramulus et folium taxi cuspidatae Extract contains the composition of following percentage by weight: paclitaxel 0.5～5, taxane diterpene-kind compound 5～25, tannin 20～30, polysaccharide 20～30, total flavones 20～30 with the application of Ramulus et folium taxi cuspidatae Extract as the oral drugs of treatment cancer.These oral drugs are tablet or capsule.Described taxane diterpene-kind compound comprises: baccatin III, 10-deacetylate baccatin III, Cephalomannine.Above-mentioned Ramulus et folium taxi cuspidatae Extract is to be that feed purification forms with the Ramulus et folium taxi cuspidatae, with paclitaxel and other multiple diterpene-kind compound with active anticancer is active ingredient, both utilize global first-class anticancer composition paclitaxel, utilized other taxanes anti-cancer active matters again.Behind paclitaxel and tannin, polysaccharide, the total flavones compatibility, eliminate or lowered the toxic and side effects of paclitaxel analog compound, improved the curative effect of medicine, and have the effect that improves body immunity.This medicine also has and carries taking convenience, advantage that cost is low, and treating with paclitaxel injection needs 60,000 yuan of RMB a course of treatment, and only needs about 3,000 yuan of RMB one course of treatment with oral drug therapy of the present invention.Drug main of the present invention will be used for the treatment of pulmonary carcinoma, ovarian cancer, breast carcinoma etc.It is obvious that this medicine is taken effect to postoperative patient, alternative or cooperate put, chemotherapy treats, the improvement of patient's pulmonary carcinoma symptom is mainly shown on cough-relieving, hemostasis, the analgesic effect, and effect is remarkable.Simultaneously patient's appetite, body constitution etc. also there is significant improvement.With oral drugs of the present invention pulmonary carcinoma, breast carcinoma, each 100 example of ovarian cancer patient are treated, cure rate, effective percentage, obvious effective rate see the following form.
| Title | Effective percentage | Cure rate | Obvious effective rate |
| Pulmonary carcinoma | ????68％ | ????50％ | ????52％ |
| Breast carcinoma | ????49％ | ????60％ | ????38％ |
| Ovarian cancer | ????30％ | ????40％ | ????23％ |
The specific embodiment one: the antitumor oral medicine of present embodiment is tablet or the capsule of being made by Ramulus et folium taxi cuspidatae Extract and starch, magnesium stearate, gelatin, and the percentage by weight of each composition is in tablet or the capsule: Ramulus et folium taxi cuspidatae Extract 70～80, starch 17～23, magnesium stearate 2～4, gelatin 1～3.Described Ramulus et folium taxi cuspidatae Extract contains the composition of following percentage by weight: paclitaxel 0.5～5, taxane diterpene-kind compound 5～25, tannin 20～30, polysaccharide 20～30, total flavones 20～30.Described Ramulus et folium taxi cuspidatae Extract is that branch, leaf, stem or the root with Ramulus et folium taxi cuspidatae is that raw material is made, and its preparation technology is: get raw material and be crushed to 50 orders; Adding concentration is the ethanol more than 85% in raw material, reflux, extract, 6～7 times, and each 4～6 hours, till extracting liquid colourless, merge extractive liquid, reclaimed ethanol; Raw material is condensed into thick paste; Reheat to 60 ℃ drying; After sieving, add starch and an amount of ethanol again, mixing is made granule, adds magnesium stearate and gelatin behind drying, the granulate, mixing, and compacting is in flakes, sugar coating is made tablet.The usage of this medicine and consumption: 40 days is a course of treatment, each 4～7 (every heavy 0.35g), every day 3 oral meals, 3～10 courses of treatment of average medication.
The specific embodiment two: what present embodiment and the specific embodiment one were different is to make capsule with Ramulus et folium taxi cuspidatae Extract.
Claims (5)
1, the antitumor oral medicine made from Ramulus et folium taxi cuspidatae Extract, it is characterized in that it is that described Ramulus et folium taxi cuspidatae Extract contains the composition of following percentage by weight: paclitaxel 0.5～5, taxane diterpene-kind compound 5～25, tannin 20～30, polysaccharide 20～30, total flavones 20～30 with the application of Ramulus et folium taxi cuspidatae Extract as the oral drugs of treatment cancer.
2, the antitumor oral medicine made from Ramulus et folium taxi cuspidatae Extract according to claim 1 is characterized in that described taxane diterpene-kind compound comprises: baccatin III, 10-deacetylate baccatin III, Cephalomannine.
3, the antitumor oral medicine made from Ramulus et folium taxi cuspidatae Extract according to claim 1, it is characterized in that medicine is the tablet of being made by Ramulus et folium taxi cuspidatae Extract and starch, magnesium stearate, gelatin, the percentage by weight of each composition is in the tablet: Ramulus et folium taxi cuspidatae Extract 70～80, starch 17～23, magnesium stearate 2～4, gelatin 1～3.
4, the antitumor oral medicine made from Ramulus et folium taxi cuspidatae Extract according to claim 1 is characterized in that making capsule with Ramulus et folium taxi cuspidatae Extract.
5,, it is characterized in that described Ramulus et folium taxi cuspidatae Extract is that branch, leaf, stem or root with Ramulus et folium taxi cuspidatae is that raw material is made according to claim 1,2, the 3 or 4 described antitumor oral medicines made from Ramulus et folium taxi cuspidatae Extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02132940 CN1413584A (en) | 2002-09-14 | 2002-09-14 | Antitumor oral medicine prepared by Chinese yew extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02132940 CN1413584A (en) | 2002-09-14 | 2002-09-14 | Antitumor oral medicine prepared by Chinese yew extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1413584A true CN1413584A (en) | 2003-04-30 |
Family
ID=4746995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02132940 Pending CN1413584A (en) | 2002-09-14 | 2002-09-14 | Antitumor oral medicine prepared by Chinese yew extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1413584A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101671319B (en) * | 2009-09-18 | 2012-02-29 | 应成杰 | Taxus nontoxic extract process |
| CN104606677A (en) * | 2014-12-15 | 2015-05-13 | 中山大学 | Taxol oral bioavailability improving taxane composition and application |
| CN104970087A (en) * | 2014-04-11 | 2015-10-14 | 信阳农林学院 | Egg preservative agent from metasequoia seeds and preparation technology thereof |
| CN109580503A (en) * | 2018-09-30 | 2019-04-05 | 东阳市杰迩威生物科技有限公司 | Chinese yew extract and detection method |
-
2002
- 2002-09-14 CN CN 02132940 patent/CN1413584A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101671319B (en) * | 2009-09-18 | 2012-02-29 | 应成杰 | Taxus nontoxic extract process |
| CN104970087A (en) * | 2014-04-11 | 2015-10-14 | 信阳农林学院 | Egg preservative agent from metasequoia seeds and preparation technology thereof |
| CN104606677A (en) * | 2014-12-15 | 2015-05-13 | 中山大学 | Taxol oral bioavailability improving taxane composition and application |
| CN104606677B (en) * | 2014-12-15 | 2018-04-03 | 中山大学 | A kind of taxanes composition for improving paclitaxel oral bioavilability and its application |
| CN109580503A (en) * | 2018-09-30 | 2019-04-05 | 东阳市杰迩威生物科技有限公司 | Chinese yew extract and detection method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han | Highlight on the studies of anticancer drugs derived from plants in China | |
| EP3391893B1 (en) | Pharmaceutical composition for treating leukemia and preparation method thereof | |
| CN109331006B (en) | Paclitaxel and elemene molecular compatible pharmaceutical composition and application thereof | |
| CN101444500A (en) | Application of iridoid in preparing anti-tumor medicine | |
| CN1413584A (en) | Antitumor oral medicine prepared by Chinese yew extract | |
| CN101134057B (en) | Compound medicament of natural plant extract containing paclitaxel and anticancer application thereof | |
| Zainuddin et al. | Antiproliferative effect of Dendrophthoe pentandra extracts towards human breast adenocarcinoma cells (MCF-7) | |
| CN1256308C (en) | Yew genus plant extract and its extraction method and application | |
| CN103446194A (en) | Anti-cancer oral medicine prepared from Chinese yew extract | |
| CN109288831B (en) | Docetaxel and elemene molecular compatible pharmaceutical composition and application thereof | |
| CN101773532B (en) | Carpesium abrotanoides total terpene lactones extract | |
| Izuegbuna | Leukemia chemoprevention and therapeutic potentials: Selected medicinal plants with anti-leukemic activities | |
| CN101444490A (en) | Injection preparation containing anhydrogalactitol and preparation method thereof | |
| Abdel-Hamid et al. | In vitro antitumor efficacy of Kochia indica extract on human hepatocellular carcinoma cell line with or without 5-fluorouracil | |
| Zainab et al. | An updated assessment on anticancer activity of screened medicinal plants in Jordan: Mini review | |
| CN104069194A (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| Agrawal et al. | In Silico Studies of Bioactive Compounds from Hibiscus rosa-sinensis Against HER2 and ESR1 for Breast Cancer Treatment | |
| Rosli et al. | Assessment of Cytotoxicity Potency of Paclitaxel in Combination with Clinacanthus Nutans Extracts on Human MDA-MB-231 Breast Cancer Cells. | |
| CN100494143C (en) | Anti-tumor compound trans-4-[2-(3,5,-dimethoxyphenyl) vinyl]-1,2-xyyl alcohol and preparing method therefor | |
| CN1194716C (en) | Chinese patent drug made by using pseudo-ginseng and epimedium as raw material for curing coronary heart disease | |
| CN114028381B (en) | Medicine for treating ovarian cancer and application thereof | |
| CN1375301A (en) | Application of pilose gerbera herb in preparing antineoplastic medicine | |
| CN111249268B (en) | Binary composition containing maduramicin and paclitaxel | |
| Crouch et al. | Bulb alkaloids of the reputedly psychoactive Brunsvigia radulosa (Amaryllidaceae) | |
| CN1093411C (en) | Anti-cancer medicinal composition and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |